|
TransMolecular reports annexin A2 is a novel binding partner for TM601 |
|
|
Potent Pleiotropic Anti-angiogenic Effects of TM601, a Synthetic Chlorotoxin Peptide |
|
|
Annexin A2 Is a Molecular Target for TM601, a Peptide with Tumor-targeting and Anti-angiogenic Effects |
Our company is committed to discovering, developing and commercializing novel, targeted therapies for cancers with limited treatment options. Our experienced team is dedicated to expediting the research and approval processes necessary to bring promising new treatment options - as well as renewed hope - to millions of patients who need them.
Our lead compound is TM601 (Chlorotoxin), for the treatment of various cancers and opthalmalogic, neo-vascular diseases. A unique tumor targeting compound, TM601 also inhibits the activity of a number of pro-angiogenic pathways, making it a versatile anti-angiogenic agent.